ArticleTherapeutic advances in medical oncology2025
Prediction of immunotherapy efficacy for pulmonary lymphoepithelioma-like carcinoma using baseline routine blood tests and serum tumor markers: a multicenter retrospective study.
Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary lymphoepithelioma-like carcinoma (pLELC) is a rare Epstein-Barr virus-associated subtype of non-small cell lung cancer. Although immune checkpoint inhibitors (ICIs) have shown promising activity, robust predictors of benefit remain lacking. Programmed death-ligand 1 (PD-L1) is widely used but has limited accuracy. Routine blood tests and serum tumor markers (STMs) are inexpensive and universally available, yet their prognostic value in pLELC has not been systematically evaluated. Objectives: To develop and validate a composite blood-based score integrating hematologic indices and STMs for predicting immunotherapy outcomes in advanced pLELC. Design: Multicenter retrospective cohort study. Methods: We retrospectively analyzed 254 patients with advanced pLELC treated with ICIs across six tertiary centers in China. Baseline hematologic indices, serum biochemistry, and STMs were collected. A composite Blood Routine & Tumor-Marker Score (BRTS) was constructed using LASSO Cox regression with progression-free survival (PFS) as the endpoint. Patients were stratified into high- and low-BRTS groups, and prognostic value was validated in an independent cohort. Nomograms combining BRTS with clinical variables were developed and internally validated. Results: High BRTS was associated with significantly shorter PFS and overall survival (OS) in both training (hazard ratio (HR) for PFS = 4.59; OS = 6.86) and validation cohorts (HR for PFS = 5.37; OS = 3.87; all Conclusion: The BRTS, derived from widely available laboratory tests, robustly stratified immunotherapy outcomes in advanced pLELC and outperformed PD-L1 alone. This simple, low-cost tool may facilitate individualized treatment decisions and warrants prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.